pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,101 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1032Endpoints784BioPharma Dive299BioSpace219Fierce Biotech207onclive165raps78globenewswire health
therapy area
allOncology6092Rare Disease1461Cardiology1094Hematology1029Immunology1009Vaccines918Pulmonology
  • The crown for healthcare admin tech is still up for grabs
    A few years in, admin tech is still reigning as the king of health tech funding. Startups using AI to tackle mundane administrative work in healthcare, such as follow-ups,
    Endpoints · 3mo ago↗ source
  • Pfizer delays patent cliff for blockbuster Vyndamax
    Pfizer is staving off Vyndamax competition for another two years. The drug, also known as tafamidis, is among Pfizer’s top three best-selling medicines and vaccines. Vyndamax is approved for a hear…
    Endpoints · 3mo ago↗ source
  • Opinion: FDA commissioner: ‘Smarter,’ real-time clinical trials could transform drug development
    “For the first time, FDA regulators will be able to see what’s happening in a clinical trial, looking at endpoints in the cloud as they occur,” writes FDA commissioner.
    STAT
← prev
page 81 of 85
next →
73
fda recalls47
fda medwatch38
fda press28
906
Psychiatry & CNS724
Ophthalmology422
Pain400
Endocrinology & Metabolism384
Infectious Disease360
· 3mo ago
↗ source
  • Hikma and Amarin's generic drug case heads to Supreme Court arguments
    When the Supreme Court hears arguments this week over a prescription-strength pill derived from fish oil, the entire generic drug industry will be watching. The case could have broad implications o…
    Endpoints · 3mo ago↗ source
  • Fauci adviser David Morens indicted on charges of concealing emails, avoiding records requests
    The charges against Morens come after Congressional probes related to the origins of the virus that causes Covid-19.
    STAT · 3mo ago↗ source
  • STAT+: Supreme Court to hear case about ‘skinny labeling’ and generic access
    The Supreme Court Wednesday will hear oral arguments about a simmering controversy over so-called skinny labels, with implications for the availability of generics.
    STAT · 3mo ago↗ source
  • Rocket's PRV goes for $180M; Oruka targets $500M offering
    Rocket sells PRV for $180M: The New Jersey gene therapy maker sold the rare pediatric disease priority review voucher to an undisclosed buyer. Rocket Pharmaceuticals got the PRV after securing FDA ...
    Endpoints · 3mo ago↗ source
  • BeOne Medicines licenses trispecific antibody targeting PD-1, CTLA-4 and VEGF
    The pharma company formerly known as BeiGene has plucked an experimental cancer drug from a Chinese biotech, aiming to go broader than its competitors. BeOne Medicines said it signed a license and…
    Endpoints · 3mo ago↗ source
  • Incyte claims double Phase 3 win in vitiligo, will file for approval
    Incyte intends to seek approval of its JAK1 inhibitor pill in the skin disease nonsegmental vitiligo after the drug, povorcitinib, hit in twin Phase 3 trials. The company revealed the successes ...
    Endpoints · 3mo ago↗ source
  • STAT+: Boehringer’s obesity drug shows 16.6% weight loss; more data needed
    Eli Lilly's deal with Profluent, Erasca's RAS-targeting cancer pill, and more biotech news today
    STAT · 3mo ago↗ source
  • STAT+: Google’s clinical director on AI challenges
    In this edition of STAT Health Tech newsletter: a conversation with Google's clinical director, an update on Doctronic's Utah experiment, and more.
    STAT · 3mo ago↗ source
  • Updated: AbbVie flirts with popular pan-RAS field in up to $1.45B option to acquire Kestrel
    The pan-RAS space continues to gain momentum, as AbbVie signs up for a shot at entering a field with the potential to drastically alter the treatment of certain cancers. The Chicago-area pharma gia…
    Endpoints · 3mo ago↗ source
  • STAT+: Pharmalittle: We’re reading about warnings over Trump’s MFN plan, Purdue Pharma sentencing, and more
    The Novartis CEO warned that Trump's drug pricing policy poses a “very difficult situation” and the reality will soon catch up with drugmakers and patients
    STAT · 3mo ago↗ source
  • FDA claims trial 'manipulation' tainted approval of ChemoCentryx drug
    The FDA accused ChemoCentryx of manipulating the results of a pivotal clinical trial used to approve the drug Tavneos, escalating the agency's effort to pull the treatment from the market. "New inf…
    Endpoints · 3mo ago↗ source
  • Devoted Health’s 2025 revenue slips in turbulent Medicare Advantage market
    Devoted Health’s revenue and membership declined in 2025 for the first time since it launched health plans for seniors seven years ago. It’s a sign the high-profile startup, helmed by former Athena…
    Endpoints · 3mo ago↗ source
  • Adaptyv Bio reveals latest results in protein design competition
    RIO DE JANEIRO, Brazil — For the past two years, Adaptyv Bio has challenged the AI community to see how good today’s models are at designing proteins. Its latest competition, presented Monday at a…
    Endpoints · 3mo ago↗ source
  • Predicting consequences of new hepatitis B vaccine recs
    New data on public trust in science, AI and mental health, and other news from Morning Rounds
    STAT · 3mo ago↗ source
  • Lilly strikes second partnership this year for recombinase-based gene editing
    Decades before CRISPR gene editing was invented, scientists tried to manipulate genes with enzymes called recombinases. The proteins were precise but proved tricky to use because they were hardwire…
    Endpoints · 3mo ago↗ source
  • Galapagos spinout Coultreon raises $125M for new take on SIK inhibition
    Coultreon Biopharma has patched together $125 million from some of the largest biotech investors in the US and Europe in a bid to join the burgeoning pipeline-in-a-pill approach to autoimmune disea…
    Endpoints · 3mo ago↗ source
  • STAT+: Eli Lilly enlists AI startup for next-generation gene editors
    Eli Lilly's deal with Profluent aims to go beyond CRISPR by using AI-designed enzymes to insert entire genes. It could reshape genetic medicine.
    STAT · 3mo ago↗ source
  • Novartis CEO disheartened by Germany’s planned €60B cuts to healthcare spending
    Novartis CEO Vas Narasimhan said the Swiss company is “very disappointed” by Germany’s plan to shave off more than €60 billion in healthcare costs that would affect pharma sales. Germany wants to s…
    Endpoints · 3mo ago↗ source
  • Boehringer, Zealand’s obesity shot looks as good as Novo's Wegovy, but weaker than Lilly's Zepbound
    Obesity patients taking the weight loss injection being developed by Boehringer Ingelheim lost nearly 17% of their weight after about a year and a half, the company said Tuesday. The results are mo…
    Endpoints · 3mo ago↗ source
  • Opinion: It’s time to seize the rare bipartisan opening to address microplastics
    “This could be the start of serious action on microplastics. Or it could end up as a headline with little behind it,” write Tim Ryan and Justin Zorn.
    STAT · 3mo ago↗ source
  • Opinion: Why do discussions about ‘brain health’ ignore mental illness?
    “Failing to adopt a more inclusive concept of brain health represents a massive loss of human potential,” write Husseini K. Manji, Eric J. Nestler, and Patrick J. Kennedy.
    STAT · 3mo ago↗ source
  • STAT+: A giant question looms over GOP’s new Medicaid work requirements
    Coverage losses tied to Medicaid work requirements may not be tracked in every states.
    STAT · 3mo ago↗ source